The ASRGL1 Knockout CAL-27 Polyclonal Cells product provides a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human tongue squamous cell carcinoma line CAL-27, engineered for loss-of-function studies of the ASRGL1 gene. This polyclonal format maintains genetic heterogeneity while achieving targeted disruption of ASRGL1, enabling robust investigation of gene function without clonal selection artifacts. The product is intended for advanced biomedical research applications, including tumor biology, metabolic signaling, and therapeutic sensitivity assays. Researchers can employ these cells to dissect ASRGL1-dependent mechanisms in a well-characterized oral cancer background, with the knockout population facilitating statistically powered experiments by averaging over multiple editing events.
CAL-27 cells originate from a tongue squamous cell carcinoma lesion and are widely utilized as a model for oral squamous cell carcinoma, exhibiting both invasive and metastatic traits that recapitulate advanced disease. The cell line serves as a reliable platform for studying oncogenic processes, drug responses, and metabolic adaptations in head and neck cancers. Its established use in the literature includes investigations of migration, invasion, and signaling pathways relevant to squamous cell carcinoma progression. By introducing an ASRGL1 knockout in this context, the product offers a physiologically pertinent system to examine how alterations in asparagine metabolism intersect with the aggressive phenotype of oral cancer cells.
The ASRGL1 gene encodes a bifunctional enzyme with L-asparaginase and isoaspartyl dipeptidase activities, catalyzing the hydrolysis of L-asparagine to aspartate and ammonia and cleaving beta-linked isoaspartyl peptides to facilitate protein repair. ASRGL1 is transcriptionally regulated by TP53 and operates within the asparagine degradation pathway, directly modulating intracellular asparagine and aspartate pools. The enzyme forms a homodimer and functionally interfaces with the mTORC1 signaling axis; its activity influences downstream phosphorylation of S6 ribosomal protein, a readout of mTORC1 activity. Within the broader metabolic network, ASRGL1 is linked to ASNS, mTOR, RHEB, and the amino acids L-asparagine and aspartate. By depleting asparagine, ASRGL1 may restrain mTORC1 signaling, positioning it as a potential tumor suppressor in cancers reliant on asparagine bioavailability.
In CAL-27 cells, targeted disruption of ASRGL1 is predicted to elevate intracellular asparagine levels, thereby activating mTORC1 signaling and potentially enhancing proliferative and survival pathways under nutrient-replete conditions. This model is particularly relevant for studying the metabolic vulnerabilities of oral squamous cell carcinoma, as many cancers exhibit dependencies on exogenous asparagine or upregulated asparagine synthetase (ASNS) expression. The knockout cells enable dissection of how ASRGL1 loss modulates response to L-asparaginase treatment or dietary asparagine restriction, providing insights into metabolic checkpoints that could be exploited therapeutically. In the context of endometrial carcinoma and other cancer types where ASRGL1 has been proposed as a tumor suppressor, this CAL-27-derived model offers a complementary oral cancer framework to validate broad oncogenic roles.
Researchers can utilize the ASRGL1 Knockout CAL-27 Polyclonal Cells for a range of applications, such as profiling ASRGL1-mediated tumor suppression via proliferation and migration assays, or quantifying mTORC1 pathway activation through phospho-S6 ribosomal protein western blotting following L-asparaginase exposure. The product supports metabolic flux analyses by measuring intracellular L-asparagine and aspartate concentrations, as well as transcriptomic profiling via RNA-seq to identify downstream targets of ASRGL1 loss. Additional characterization with RT-qPCR and western blotting for ASRGL1 confirms knockout status, while L-asparaginase sensitivity assays evaluate therapeutic vulnerability. For detailed technical inquiries or custom applications, please contact Ascent Research.
